Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty
Author(s) -
Brian F. Gage,
Anne R. Bass,
Hannah Lin,
Scott C. Woller,
Scott M. Stevens,
Noor AlHammadi,
Juan Li,
Tomás Navarro–Rodriguez,
J. Philip Miller,
Gwendolyn A. McMillin,
Robert C. Pendleton,
Amir K. Jaffer,
Cristi R. King,
Brandi DeVore Whipple,
Rhonda Porche-Sorbet,
Lynnae Napoli,
Kerri Merritt,
Anna M. Thompson,
Gina Hyun,
Jeffrey L. Anderson,
Wesley Hollomon,
Robert L. Barrack,
Ryan M. Nunley,
Gerard Moskowitz,
Víctor G. DávilaRomán,
Charles S. Eby
Publication year - 2017
Publication title -
jama
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.688
H-Index - 680
eISSN - 1538-3598
pISSN - 0098-7484
DOI - 10.1001/jama.2017.11469
Subject(s) - medicine , warfarin , dosing , randomized controlled trial , vkorc1 , deep vein , adverse effect , arthroplasty , surgery , cyp2c9 , thrombosis , atrial fibrillation , cytochrome p450 , metabolism
Warfarin use accounts for more medication-related emergency department visits among older patients than any other drug. Whether genotype-guided warfarin dosing can prevent these adverse events is unknown.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom